Switch theme
Sign up to access all valuation multiples
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
2007
66
LTM Revenue $24.3M
Last FY EBITDA -$76.0M
$81.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cartesian Therapeutics has a last 12-month revenue (LTM) of $24.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cartesian Therapeutics achieved revenue of $38.9M and an EBITDA of -$76.0M.
Cartesian Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cartesian Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $24.3M | XXX | $38.9M | XXX | XXX | XXX |
| Gross Profit | $24.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$76.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -195% | XXX | XXX | XXX |
| EBIT | -$65.4M | XXX | -$36.3M | XXX | XXX | XXX |
| EBIT Margin | -270% | XXX | -93% | XXX | XXX | XXX |
| Net Profit | -$81.5M | XXX | -$77.4M | XXX | XXX | XXX |
| Net Margin | -336% | XXX | -199% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cartesian Therapeutics's stock price is $10.
Cartesian Therapeutics has current market cap of $248M, and EV of $81.8M.
See Cartesian Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $81.8M | $248M | XXX | XXX | XXX | XXX | $-4.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cartesian Therapeutics has market cap of $248M and EV of $81.8M.
Cartesian Therapeutics's trades at 2.1x EV/Revenue multiple, and -1.1x EV/EBITDA.
Equity research analysts estimate Cartesian Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cartesian Therapeutics has a P/E ratio of -3.0x.
See valuation multiples for Cartesian Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $248M | XXX | $248M | XXX | XXX | XXX |
| EV (current) | $81.8M | XXX | $81.8M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBIT | -1.3x | XXX | -2.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCartesian Therapeutics's last 12 month revenue growth is -91%
Cartesian Therapeutics's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $1.1M for the same period.
Cartesian Therapeutics's rule of 40 is -995% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cartesian Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cartesian Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -91% | XXX | -90% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -195% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -995% | XXX | -286% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 116% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 193% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cartesian Therapeutics acquired XXX companies to date.
Last acquisition by Cartesian Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cartesian Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cartesian Therapeutics founded? | Cartesian Therapeutics was founded in 2007. |
| Where is Cartesian Therapeutics headquartered? | Cartesian Therapeutics is headquartered in United States of America. |
| How many employees does Cartesian Therapeutics have? | As of today, Cartesian Therapeutics has 66 employees. |
| Who is the CEO of Cartesian Therapeutics? | Cartesian Therapeutics's CEO is Dr. Carsten Brunn, PhD. |
| Is Cartesian Therapeutics publicy listed? | Yes, Cartesian Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cartesian Therapeutics? | Cartesian Therapeutics trades under RNAC ticker. |
| When did Cartesian Therapeutics go public? | Cartesian Therapeutics went public in 2016. |
| Who are competitors of Cartesian Therapeutics? | Similar companies to Cartesian Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cartesian Therapeutics? | Cartesian Therapeutics's current market cap is $248M |
| What is the current revenue of Cartesian Therapeutics? | Cartesian Therapeutics's last 12 months revenue is $24.3M. |
| What is the current revenue growth of Cartesian Therapeutics? | Cartesian Therapeutics revenue growth (NTM/LTM) is -91%. |
| What is the current EV/Revenue multiple of Cartesian Therapeutics? | Current revenue multiple of Cartesian Therapeutics is 3.4x. |
| Is Cartesian Therapeutics profitable? | Yes, Cartesian Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
